688289 Sansure Biotech Inc.
- 20.14
- +0.20+1.00%
Sansure Biotech Inc. News
Looking for the 3 billion market? Shengxiang Biological Water Test Rapid Drug Sensitivity Test Track
① “We still do it in the form of strategic investment rather than financial investment. Newly established companies are not included in the scope of the company's statements.” ② If Hunan Shengwei Sumin's subsequent business becomes more mature, it is not ruled out that Shengxiang Biotech will take more actions other than strategic investment.
Shengxiang Biology (688289): Rapid development of respiratory testing business drives both revenue and profitability
Incident: Shengxiang Biotech released its 2023 annual report and 2024 quarterly report for the year 2023. The company achieved operating income of 1,007 billion yuan/ -84.39%; net profit to mother was 364 million yuan/-81.22
Shengxiang Biotech (688289.SH) plans to establish a new joint venture with the Industrial Fund to focus on the field of rapid drug sensitivity testing
Shengxiang Biology (688289.SH) announced that the company intends to partner with the relevant party Hunan Xiangjiang Shengxiang Biological Industry Fund...
Express News | Shengxiang Biotech: Plans to jointly invest in joint ventures with related parties
Express News | Shengxiang Biology: Plans to jointly invest in Hunan Shengwei Zumin with related parties
Shengxiang Biology (688289.SH): Plans to invest in Hunan Shengwei Sumin with related parties and transfer shares in the participating company FirstLight
On May 8, Ge Longhui Biotech (688289.SH) announced that it plans to jointly invest in the joint venture Hunan Shengwei Sumin Biotechnology Co., Ltd. (“Hunan Shengwei Sumin”) with the related party Hunan Xiangjiang Shengxiang Biological Industry Fund (limited partnership), of which the company's total investment amount is RMB 53.33 million. At the same time, the company plans to transfer 21.69% of the shares in the participating company FirstLightDiagnostics, Inc. (“FirstLight”) to a wholly-owned subsidiary of the joint venture with a consideration of 2,215,8
Shengxiang Biology (688289): Breathing brightly, thick, thin hair
Key investment performance: In 2023, the company's revenue was 1.01 billion yuan, YOY -84.4%, net profit to mother 360 million yuan, YOY -81.2%, net profit of non-return to mother 71.65 million yuan, YOY
Shengxiang Biology (688289): Significant release of respiratory joint testing products explores a new blue ocean in the home market
Incident The company published its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 1,007 million yuan (yoy -84.39%) and realized net profit of 364 million yuan (yoy-8)
Sansure Biotech's (SHSE:688289) Earnings Quality Is Low
After announcing weak earnings, Sansure Biotech Inc.'s (SHSE:688289) stock was strong. Despite the strength in the stock, we feel that investors should be cautious about some numbers in the earnings.
Shengxiang Biology (688289): Demand for respiratory products increased, revenue from conventional reagents doubled in 2023
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 1.007 billion yuan (yoy -84.39%) and net profit to mother of 364 million yuan (yoy-81.
Sansure Biotech Inc.'s (SHSE:688289) Shares May Have Run Too Fast Too Soon
Sansure Biotech Inc.'s (SHSE:688289) price-to-sales (or "P/S") ratio of 10.8x might make it look like a strong sell right now compared to the Medical Equipment industry in China, where around half of
Shengxiang Biotech (688289.SH): Net profit of 81.025 million yuan in the first quarter increased 35.01% year-on-year
On April 26, Ge Longhui (688289.SH) released its report for the first quarter of 2024, achieving operating income of 391 million yuan, an increase of 100.31%; net profit attributable to shareholders of listed companies of 81.025 million yuan, an increase of 35.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 73.755 million yuan, an increase of 1962.06% year on year; basic earnings per share of 0.14 yuan.
Express News | Shengxiang Biotech: Net profit forecast to increase 35.79% in the first quarter of 2024
Sansure Biotech (SHSE:688289) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Shengxiang Biology (688289): The performance report is in line with expectations, leading molecular diagnostics companies are growing rapidly
Core view In the short term, with the significant increase in domestic PCR production capacity, testing efficiency and clinical awareness, the molecular diagnosis penetration rate is expected to increase rapidly. As an industry leader, the company is expected to achieve rapid development in the fields of respiratory, maternal and child, and blood screening
Investors Will Want Sansure Biotech's (SHSE:688289) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expandi
Zhu Jinwei, shareholder of Shengxiang Biotech (688289.SH), reduced his holdings by 2% and the reduction period expired
Zhitong Finance App News, Shengxiang Biotech (688289.SH) issued an announcement. As of the disclosure date of this announcement, shareholder Zhu Jinwei had reduced his holdings of the company's shares by a total of 11.754,600 shares through centralized bidding transactions, accounting for 2% of the company's total shares. The time range for this holdings reduction plan has expired, and implementation has been completed.
Shengxiang Biotech (688289.SH): Net profit in 2023 fell 81.4% year on year
Gelonghui, Feb. 28, 丨 Shengxiang Biotech (688289.SH) announced its 2023 annual results report. Total operating revenue was RMB 1.06.4675 million, down 84.40% year on year, and net profit attributable to owners of the parent company was RMB 362.321 million, down 81.4% year on year. The company's total revenue and operating profit indicators for 2023 fell by more than 30% year-on-year, mainly due to changes in domestic and foreign public health prevention and control policies, which led to a sharp drop in demand for COVID-19 nucleic acid detection reagents and instruments, and a decline in related business revenue. Decrease in owners' equity vested in the parent company in 2023
Declining Stock and Decent Financials: Is The Market Wrong About Sansure Biotech Inc. (SHSE:688289)?
With its stock down 9.8% over the past month, it is easy to disregard Sansure Biotech (SHSE:688289). However, stock prices are usually driven by a company's financials over the long term, which in t
Express News | Nearly 20 listed companies disclosed plans to repurchase or increase their holdings up to 100 million yuan after the market and announced the repurchases of Precision Measurement Electronics, Yiqiao Shenzhou, and Shunwang Technology for cancellation
Analysis
Price Target
No Data
